Cord blood for brain injury

Sun, Jessica; Kurtzberg, Joanne

doi:10.1016/j.jcyt.2015.03.004

Cited by 28 publications

(23 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Financial strain to the company sponsor of these neuroteratocarcinoma cells contributed to abandoning this clinical trial, prompting the search for alternative transplantable cells. Adult tissue‐derived stem cells, including those harvested from bone marrow, umbilical cord, and adipose, eventually took center stage and to date remain as the front‐runner cell source for cell therapy for stroke .…”

Section: Stem Cell Therapy For Stroke Has Reached Clinical Trials Thmentioning

confidence: 99%

Concise Review: Stem Cell Therapy for Stroke Patients: Are We There Yet?

Borlongan

2019

Stem Cells Translational Medicine

113

102

View full text Add to dashboard Cite

Four decades of preclinical research demonstrating survival, functional integration, and behavioral effects of transplanted stem cells in experimental stroke models have provided ample scientific basis for initiating limited clinical trials of stem cell therapy in stroke patients. Although safety of the grafted cells has been overwhelmingly documented, efficacy has not been forthcoming. Two recently concluded stroke clinical trials on mesenchymal stem cells (MSCs) highlight the importance of strict adherence to the basic science findings of optimal transplant regimen of cell dose, timing, and route of delivery in enhancing the functional outcomes of cell therapy. Echoing the Stem Cell Therapeutics as an Emerging Paradigm for Stroke and Stroke Treatment Academic Industry Roundtable call for an NIH‐guided collaborative consortium of multiple laboratories in testing the safety and efficacy of stem cells and their derivatives, not just as stand‐alone but preferably in combination with approved thrombolytic or thrombectomy, may further increase the likelihood of successful fruition of translating stem cell therapy for stroke clinical application. The laboratory and clinical experience with MSC therapy for stroke may guide the future translational research on stem cell‐based regenerative medicine in neurological disorders. stem cells translational medicine 2019;8:983&988

show abstract

Section: Stem Cell Therapy For Stroke Has Reached Clinical Trials Thmentioning

confidence: 99%

Concise Review: Stem Cell Therapy for Stroke Patients: Are We There Yet?

Borlongan

2019

Stem Cells Translational Medicine

113

102

View full text Add to dashboard Cite

show abstract

“…It has been shown that UCB‐SC treatment plays a neural‐restorative and neural‐regenerative role in premature brain injuries (Sun & Kurtzberg, ) (Figure ). Some UCB‐SCs likely differentiate into “replacement” glial cells and neurons and integrate into the host brain where they play a role in re‐myelination (Sato et al, ; Shen et al, ).…”

Section: Mechanisms Of Ucb‐sc Therapymentioning

confidence: 99%

Umbilical cord blood stem cell therapy in premature brain injury: Opportunities and challenges

Peng

Shi

et al. 2019

J of Neuroscience Research

View full text Add to dashboard Cite

Preterm birth and associated brain injury are the primary cause of cerebral palsy and developmental disabilities and are among the most serious global health issues that modern society faces. Current therapy for infants suffering from premature brain injury is still mainly supportive, and there are no effective treatments. Thus there is a pressing need for comparative and translational studies on how to reduce brain injury and to increase regeneration and brain repair in preterm infants. There is strong supporting evidence for the use of umbilical cord blood (UCB)‐derived stem cell therapy for treating preterm brain injury and neurological sequelae. UCB‐derived stem cell therapy is effective in many animal models and has been shown to be feasible in clinical trials. Most of these therapies are still experimental, however. In this review, we focus on recent advances on the efficacy of UCB‐derived stem cell therapy in preterm infants with brain injury, and discuss the potential mechanisms behind their therapeutic effects as well as application strategies for future preclinical and clinical trials.

show abstract

“…mononuclear cells are protective in several in vitro culture and animal models of CNS injury (reviewed in ref. 18), and CB CD14 + cells are essential for the protective ability of intravenously injected CB mononuclear cells in the rat middle cerebral artery occlusion model of stroke (19).…”

Section: Introductionmentioning

confidence: 99%